Cancer Stem Cell Screening via HLA Expression Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to consistently identify and target cancer stem cells (CSCs) due to variability in their characteristics and refractoriness to standard chemotherapy, leading to recurrence of tumors as CSCs evade treatment.
Innovation Solution
A method involving high throughput screening to identify agents that selectively decrease CSCs by contacting CSCs with candidate agents and determining their impact on survival, growth, or differentiation, using markers such as HLA negativity, CD24, CD133, and cytokeratin expression, to find agents that reduce CSC populations effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard chemotherapy treatments are used to eradicate cancer cells, then the fastest dividing cells are eliminated resulting in initial tumor shrinkage, but cancer stem cells survive and cause tumor recurrence
Solution Approach 1:
The patent segments the tumor cell population into differentiated cancer cells and cancer stem cells (CSCs) based on HLA class I expression levels. This segmentation allows for selective targeting of CSCs (HLA-negative or low-expressing) while preserving differentiated cells, thereby addressing the limitation of standard chemotherapy that treats all cells uniformly and fails to eliminate the recalcitrant CSC subpopulation.
Solution Approach 2:
The patent applies local quality by developing agents with specific properties tailored to target CSCs based on their unique HLA class I expression characteristics. The screening methods identify compounds that selectively affect HLA-negative or low-expressing cells through mechanisms such as enhanced apoptosis induction or differentiated cell fate modulation, rather than using non-specific cytotoxic agents that affect all tumor cells equally.
2Reliability
If cancer stem cells are targeted for identification and treatment, then tumor recurrence may be prevented, but the heterogeneity and variability of CSC characteristics make consistent identification difficult
Solution Approach 1:
The patent establishes HLA class I expression status as a universal marker for CSC identification across multiple cancer types. This universal approach simplifies the identification process by providing a consistent, multi-functional marker that can be used for both diagnosing CSC presence and guiding therapeutic agent selection, thereby reducing the complexity associated with tumor-specific CSC heterogeneity.
Solution Approach 2:
The patent utilizes parameter changes in HLA class I expression levels (from high to low or absent) as a defining characteristic of CSCs. This parameter-based approach allows for quantitative identification and sorting of CSCs using flow cytometry and other detection methods, transforming the complex qualitative problem of CSC identification into a measurable parameter that can be consistently assessed across different tumor samples.
3Productivity
If high throughput screening methods are used to identify CSC-targeting agents, then agents that selectively decrease CSCs can be found, but the screening process requires complex assays to differentiate CSCs from other cancer cells
Solution Approach 1:
The patent employs color changes through fluorescently labeled antibodies that bind to HLA class I molecules on cell surfaces. This allows for rapid visual and instrumental detection of CSCs (which show low or no fluorescence) versus differentiated cancer cells (which show high fluorescence) during high-throughput screening, greatly simplifying the differentiation process compared to functional assays.
Solution Approach 2:
The patent uses flow cytometry and other detection technologies to create optical copies or representations of CSC populations based on their HLA expression profiles. These copied signals allow for rapid, automated analysis of large numbers of cells without requiring complex functional differentiation assays, thereby enabling high-throughput screening while reducing measurement difficulty.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth of the CSC or increases differentiation of the CSC relative to a CSC that has not been contacted with the candidate agent. The method may be used as a high throughput screen.